Affordable Access

Access to the full text

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma

Authors
  • Ikeda, Kenji1, 2
  • Kawamura, Yusuke1, 2
  • Kobayashi, Masahiro1, 2
  • Kominami, Yoko1, 2
  • Fujiyama, Shunichiro1, 2
  • Sezaki, Hitomi1, 2
  • Hosaka, Tetsuya1, 2
  • Akuta, Norio1, 2
  • Saitoh, Satoshi1, 2
  • Suzuki, Fumitaka1, 2
  • Suzuki, Yoshiyuki1, 2
  • Arase, Yasuji1, 2
  • Kumada, Hiromitsu1, 2
  • 1 Toranomon Hospital, Department of Hepatology, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan , Tokyo (Japan)
  • 2 Okinaka Memorial Institute of Medical Research, Tokyo, Japan , Tokyo (Japan)
Type
Published Article
Journal
Digestive Diseases and Sciences
Publisher
Springer-Verlag
Publication Date
Sep 07, 2017
Volume
62
Issue
10
Pages
2932–2942
Identifiers
DOI: 10.1007/s10620-017-4739-z
Source
Springer Nature
Keywords
License
Yellow

Abstract

BackgroundSuppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular carcinoma (HCC).Patients and MethodsA total of 177 patients received DAA after curative manners of HCC: 89 patients underwent DAA therapy after initial HCC treatment, and the other 88 patients after repeated therapy of 2–10 times. Among a cohort of HCC patients with surgery and radiofrequency ablation, 89 patients were chosen adjusting age, gender, and Barcelona Clinic Liver Cancer (BCLC) staging with 89 patients with initial HCC therapy.ResultsHCC recurrence rates at the end of first and second year were 18.1 and 22.1% in patients with once of HCC therapy, 28.2 and 41.6% in those with 2–3 times of therapy, and 60.2 and 74.5% in those with 4 or more times of therapy, respectively (P < 0.0001). Recurrence rates were compared between 89 patients with DAA therapy after initial HCC therapy and 89 age-, gender-, and BCLC staging-matched patients without antiviral therapy after initial HCC therapy. HCC recurrence rates at first and second year were 18.1 and 25.0% in patients with DAA therapy and 21.8 and 46.5% in those without DAA therapy, respectively (P = 0.003). Multivariate analysis showed DAA therapy significantly decreased recurrence rate with a hazard ratio of 0.353 (confidence interval: 0.191–0.651) after adjustment with covariates of tumor multiplicity, alpha-fetoprotein value, and prothrombin time.ConclusionsDAA therapy significantly decreased recurrence rate when it was performed after initial HCC therapy.

Report this publication

Statistics

Seen <100 times